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ABSTRACT

ARTICLE HISTORY

Langerhans cell histiocytosis (LCH) is a rare malignancy most commonly characterized by
histiocytic infiltration of bone. LCH lesions in the skull place the adjacent central nervous
system (CNS) at risk for involvement, which can manifest as central diabetes insipidus (CDI)
when there is infiltration of the hypothalamic-pituitary axis. We present a case of a 39-yearold female who presented with polyuria and polydipsia for 1 year and left-sided hearing loss,
gait instability, and nystagmus for 5 days. She was found on laboratory evaluation to have
CDI and underwent left cortical mastoidectomy for a destructive peripherally enhancing
mastoid lesion seen on MRI brain. Pathology revealed CD1a and S100+ LCH and the patient
was subsequently discharged to begin outpatient chemotherapy with vinblastine and prednisone. The patient’s CDI was diagnostic of CNS involvement, making her LCH multisystem
through the infiltration of both the skull and hypothalamic-pituitary structures. As CDI can be
seen in up to 25% of single-system LDH, and up to 50% of multisystem cases, radiologic
studies to evaluate for osteolytic skull lesions must be considered as part of the evaluation for
LCH when CDI has been diagnosed.
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1. Introduction
Langerhans cell histiocytosis (LCH) is a rare
malignancy characterized by lesions of monoclonal histiocytes capable of infiltrating almost any
organ system. This disease is also known by its
previous monikers, Histiocytosis X and eosinophilic granulomas, or by its eponymous labels,
Letterer–Siwe disease, Hand–Schüller–Christian
disease, and Hashimoto–Pritzker disease. Even its
own name is a potential misnomer, as recent studies have suggested that the malignant cell is
actually a dendritic precursor from the bone marrow instead of a transformed Langerhans cell from
the epidermis [1]. Largely a disease of children, its
incidence in adults approximates 1–2 cases
per million with a mean age of 35 ± 14 years at
diagnosis [2]. LCH is classified based on organ
involvement into single-system (usually bones or
lungs in adults) versus multisystem disease. The
latter is further stratified into low and high-risk
groups, distinguished by the involvement of risk
organs (the hematopoietic system, liver, and
spleen) which carries worse prognoses [3,4].
There is skeletal system involvement in most
cases, and LCH lesions within the skull place the
disease within close proximity to the central nervous system (CNS). Lesions are deemed CNS-risk
if they occur in the orbital, temporal, sphenoidal,
ethmoidal, or mastoid bones or the paranasal
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sinuses or the anterior/middle cranial fossae.
CNS involvement can manifest as central diabetes
insipidus (CDI) through the infiltration of the
hypothalamic-pituitary structures. CDI can be
seen in up to 25% of all LCH cases, in multisystem
disease the rate climbs up to 50% of the cases [5].
Diagnosis is biopsy-driven, with typical microscopic findings including granulomatous pathology with mononuclear cells with indented nuclei
accompanied by lymphocytes and eosinophils.
Confirmation of the diagnosis requires histological
staining for markers such as CD1a and S100 [2].
Treatment is tailored to organ involvement and
can range from surgical curettage to systemic chemotherapy. The latter is indicated for multisystem
LCH, CNS-risk lesions, and particular cases of
multifocal osseous involvement [4].

2. Case description
A 39-year-old female with a past medical history of
Sjogren’s syndrome on hydroxychloroquine, iron deficiency anemia, and hypothyroidism presented with polydipsia and polyuria for 1 year and left-sided hearing loss,
nausea, and gait instability over the past 5 days. On
physical exam, vital signs were stable. There were 3
beats of end-point horizontal nystagmus noted with left
gaze. The rest of the cranial nerve exam was unremarkable. She had 5/5 muscle strength in the upper and lower
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extremities. Finger-to-nose and heel-to-shin tests were
normal.
Initial laboratory workup revealed sodium 141
mmol/L, serum osmolality 301 mOsm/kg, urine
osmolality 139 mOsm/kg, HbA1C 5.0%, and TSH
4.747 μIU/mL. A 24-hr urine volume was 9,750 mL.
A water deprivation test was conducted, during
which time urine osmolality remained 173 mOsm/
kg but serum sodium increased to 146 mmol/L.
Following an IV desmopressin 4 mcg injection, her
urine osmolality peaked at 656 mOsm/kg and serum
sodium decreased to 143 mmol/L. With central diabetes insipidus diagnosed, she was started on PO
desmopressin 0.05 mg daily which caused complete
resolution of her symptoms.
An MRI of the pituitary was unremarkable but
incidentally showed an extra-axial mass that was
explored further with an MRI brain. This subsequent imaging revealed bilateral extra-axial enhancing masses (1.5 × 0.8 cm lesion in the right
parietal region and 3.4 × 0.8 cm lesion in the left
parietal region), a destructive peripherally enhancing lesion in the left mastoid, and a few scattered
small bright T2 nonspecific foci in the periventricular white matter. ENT and neurosurgery were
consulted who proceeded with left cortical mastoidectomy for the radiographically destructive
inflammatory lesion.
Pathology revealed Langerhans cell histiocytosis
(LCH) and immunoperoxidase workup showed positive
staining with CD1a and S100. She was discharged in
stable condition and referred to hematology-oncology
who ordered PET/CT scan which was remarkable for
hypermetabolic lytic lesions involving the biparietal calvarium, left mastoid temporal bone, distal right clavicle,
L2 vertebra, and left iliac wing. Of note, the lungs, liver,
and spleen were not involved, and as the patient did not
have cytopenias, bone marrow biopsy was not deemed
necessary. She was subsequently started on chemotherapy with vinblastine and prednisone.

3. Discussion
The label Langerhans cell histiocytosis (LCH)
derived from histologic studies of biopsied lesions.
It was noted that the malignant histiocytes contain
Birbeck granules and the protein langerin
(CD207), both associated with Langerhans cells
(LC), and it was postulated that the epidermal
LC underwent a malignant transformation in
LCH. However, a subsequent cytologic study illustrated that the dendritic cells that form LCH
lesions are actually precursors from the bone marrow that travel to lesion sites and differentiate into
langerin+ cells, a theory termed the ‘Misguided

Myeloid Dendritic Cell Precursor’ model [1].
Animal studies confirmed the identity of LCH as
a myeloid neoplasia by demonstrating that inducing a point mutation implicated in the disease’s
pathogenesis, BRAF-V600E, in bone marrow dendritic cell progenitors resulted in a phenotype
mimicking high-risk LCH in humans, while inducing the same mutation in differentiated dendritic
cells resulted in a low-risk LCH phenotype [6].
Our patient had multifocal bone disease,
including a CNS-risk lesion in the left mastoid.
Her central diabetes insipidus (CDI) is
a diagnostic of CNS involvement, making her
overall LCH multisystem. The circumventricular
organs, including the posterior pituitary, are particularly vulnerable to LCH infiltration due to the
absence of a blood-brain barrier. As our patient
had an unremarkable MRI of her pituitary gland,
the presence of CDI suggests that another part of
the hypothalamic-pituitary axis was involved. Our
patient was fortunate in that LCH was diagnosed
soon after her CDI was detected, and in some
cases, the LCH is discovered years after CDI manifests [7]. Eventually, anterior pituitary involvement can occur in up to 60% of LCH cases with
CDI, causing further hormonal derangements.
Additional patterns of CNS involvement include
lesions of the cerebellum and brainstem as well as
infiltration of the hypothalamus [5].
Treatment of LCH is dependent upon organ
involvement and the extent of disease. Our patient
had multisystem disease, involvement of a CNS-risk
region, and multifocal bone disease, thus systemic
therapy was indicated. Notably, she had no risk
organ involvement, which improves her overall
prognosis. She was placed on the vinca alkaloid
vinblastine and prednisone. This chemotherapeutic
regimen is standard therapy for children and was
validated in a series of three pediatric clinical trials
by the Histiocyte Society [8–10]. Seeking to examine its efficacy in adults, a recent multicenter retrospective study was conducted on 35 adult LCH
patients: 80% with multisystem disease, 89% without risk organ involvement, and 40% with CDI.
The cohort was treated with vinblastine 6 mg/m2
for at least 6 weeks and prednisone 40 mg/m2 (our
patient was placed on an identical regimen). At the
end of the treatment period, 71% of the patients
had responded (defined as either complete resolution or regression); however, the disease did recur
in 40% of this subset. The risk of reactivation/
worsening was not affected by disease location or
by the presence of multisystem disease [4].
Appropriate management of LCH-induced CDI
involves prompt diagnosis as early intervention
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with chemotherapy can reverse CDI and prevent
the later development of anterior pituitary hormonal deficiencies (APHD) or neuro�degenerative disease [11].
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